TOP TEN perturbations for 40049_at (Homo sapiens)
Organism: Homo sapiens
Gene: 40049_at
Selected probe(set): 203139_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 40049_at (203139_at) across 6674 perturbations tested by GENEVESTIGATOR:
glioma study 16 (LN-229) / normal astrocyte sample
Relative Expression (log2-ratio):-5.1130857Number of Samples:2 / 3
| Experimental | glioma study 16 (LN-229) |
| Human glioma cell line LN229 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2. | |
| Control | normal astrocyte sample |
| Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations. |
bronchial epithelial cell differentiation study 1 (day28) / bronchial epithelial cell differentiation study 1 (confluent)
Relative Expression (log2-ratio):4.7026873Number of Samples:3 / 3
| Experimental | bronchial epithelial cell differentiation study 1 (day28) |
| Differentiated normal human bronchial epithelial cell (NHBE) cultured for 28 days in an air-liquid interface (ALI) system. At this time point cells were fully differentiated and formed a polarized, pseudostratified mucociliary epithelium. In order to generate the ALI culture, undifferentiated cells were grown under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. When cells reached confluency (after 3-5 days), an air-liquid interface culture (ALI system) was created by removing the apical medium and replacing the medium of the basal compartment with B-ALI differentiation medium. During the 28 days culture medium was replaced every 48 hour. | |
| Control | bronchial epithelial cell differentiation study 1 (confluent) |
| Confluent undifferentiated normal human bronchial epithelial cell (NHBE) cultured for 3-5 days under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. At this time point cells formed a monolayer covering the whole surface of the insert. |
AsPC-1 / BxPC-3
Relative Expression (log2-ratio):-4.7003517Number of Samples:3 / 3
| Experimental | AsPC-1 |
| Human xenograft derived metastatic cancer cell line derived from mouse xenografts initiated with metastatic cells from the ascites derived from a 62 years old female Caucasian patient with pancreatic adenocarcinoma. Synonyms:AsPc-1; Aspc-1; ASPC-1; As-PC1; ASPC1; AsPC1; Aspc1; AsPc1 Cellosaurus code: | |
| Control | BxPC-3 |
| Human pancreatic adenocarcinoma cell line derived from a 61 years old female patient. Synonyms:BxPc-3; BXPC-3; Bx-PC3; BXPC3; BxPC3; BxPc3 Cellosaurus code: |
bronchial epithelial cell differentiation study 1 (day28) / bronchial epithelial cell differentiation study 1 (subconfluent)
Relative Expression (log2-ratio):4.5709534Number of Samples:3 / 3
| Experimental | bronchial epithelial cell differentiation study 1 (day28) |
| Differentiated normal human bronchial epithelial cell (NHBE) cultured for 28 days in an air-liquid interface (ALI) system. At this time point cells were fully differentiated and formed a polarized, pseudostratified mucociliary epithelium. In order to generate the ALI culture, undifferentiated cells were grown under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. When cells reached confluency (after 3-5 days), an air-liquid interface culture (ALI system) was created by removing the apical medium and replacing the medium of the basal compartment with B-ALI differentiation medium. During the 28 days culture medium was replaced every 48 hour. | |
| Control | bronchial epithelial cell differentiation study 1 (subconfluent) |
| Subconfluent undifferentiated normal human bronchial epithelial cell (NHBE) cultured for 1-2 days under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. At this time point cells still grew dispersed in the culture insert and covered 70% of the insert. |
precursor-B-ALL study 3 (PAX5-rearranged) / precursor-B-ALL study 3 (hyperdiploid)
Relative Expression (log2-ratio):-4.4629936Number of Samples:6 / 17
| Experimental | precursor-B-ALL study 3 (PAX5-rearranged) |
| Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [dic(9;20)(p11-13;q11) )/PAX5 rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). | |
| Control | precursor-B-ALL study 3 (hyperdiploid) |
| Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL (hyperdiploidy). Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). |
precursor-B-ALL study 3 (PAX5-rearranged) / precursor-B-ALL study 3 (BCR-ABL)
Relative Expression (log2-ratio):-4.431117Number of Samples:6 / 4
| Experimental | precursor-B-ALL study 3 (PAX5-rearranged) |
| Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [dic(9;20)(p11-13;q11) )/PAX5 rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). | |
| Control | precursor-B-ALL study 3 (BCR-ABL) |
| Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(9;22)(q34;q11.2)/BCR-ABL1]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). |
precursor-B-ALL study 3 (PAX5-rearranged) / T-ALL study 3
Relative Expression (log2-ratio):-4.393527Number of Samples:6 / 29
| Experimental | precursor-B-ALL study 3 (PAX5-rearranged) |
| Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [dic(9;20)(p11-13;q11) )/PAX5 rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). | |
| Control | T-ALL study 3 |
| Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). |
precursor-B-ALL study 3 (hyperdiploid) / precursor-B-ALL study 3 (MLL-rearranged)
Relative Expression (log2-ratio):4.3178806Number of Samples:17 / 5
| Experimental | precursor-B-ALL study 3 (hyperdiploid) |
| Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL (hyperdiploidy). Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). | |
| Control | precursor-B-ALL study 3 (MLL-rearranged) |
| Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(v;11q23)/MLL rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). |
precursor-B-ALL study 3 (MLL-rearranged) / precursor-B-ALL study 3 (BCR-ABL)
Relative Expression (log2-ratio):-4.286004Number of Samples:5 / 4
| Experimental | precursor-B-ALL study 3 (MLL-rearranged) |
| Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(v;11q23)/MLL rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). | |
| Control | precursor-B-ALL study 3 (BCR-ABL) |
| Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(9;22)(q34;q11.2)/BCR-ABL1]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). |
precursor-B-ALL study 3 (MLL-rearranged) / T-ALL study 3
Relative Expression (log2-ratio):-4.248414Number of Samples:5 / 29
| Experimental | precursor-B-ALL study 3 (MLL-rearranged) |
| Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(v;11q23)/MLL rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). | |
| Control | T-ALL study 3 |
| Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). |